All section Close
Cipla Celebrates World COPD Day By Launching India's First Portable Spirometer
Writer: Ratika Rana
Her primary objective is to inform, promote, educate and cultivate readers through writing.
India, 17 Nov 2021 9:54 AM GMT
Editor : Ankita Singh |
A literature lover who likes delving deeper into a wide range of societal issues and expresses her opinions about the same. Keeps looking for best-read recommendations while enjoying her coffee and tea.
Creatives : Ratika Rana
Her primary objective is to inform, promote, educate and cultivate readers through writing.
The launch of India's first portable and wireless spirometer by pharma major Cipla is aimed at an early diagnosis of chronic obstructive pulmonary disorder (COPD) and asthma.
One of the major drug companies in India, Cipla, announced the launch of Spirofy. It is India's first pneumotach based portable, wireless Spirometer. With the device's launch, the company aims at early detection of Chronic Obstructive Pulmonary Disorder (COPD) and Asthma. Cipla envisions strengthening its position as a Lung leader in the market and completely revolutionizing the diagnosis for Obstructive Airway Disease (OAD). The launch is a part of the #LungAttack campaign by the company that endeavours to increase awareness about pulmonary disorders.
Superior Quality, Real-Time Results
The official statement by Cipla defined Spirofy as a wireless device with a strong battery backup that enables its use in outdoor locations and remote areas that have power shortages. The advanced technology embedded in the devices ensures superior quality results and patient safety while using bacterial, viral filters. The company was able to develop the device after in-depth research of five years. The Spirometer can generate results in real-time, which could be printed using a portable wireless thermal printer instantly, or a pdf version of the report could be viewed on one's mobile phone.
Umang Vohra, the MD and CEO of Cipla Limited, said at the launch event, "Cipla has been steadfastly focused on addressing the world's growing respiratory disease burden, and with this launch, we see ourselves steadily advancing to combat chronic respiratory ailments like COPD. The Spirofy launch aims to help doctors across the country improve patients' lives through accurate and affordable diagnosis", LiveMint reported.
10% Rise In Revenue
Cipla recorded a net profit of ₹711 crores on a 10% rise in total revenue from operations to Rs 5,520 crore in Q2 FY22 over Q2 FY21. The net profit grew 7 per cent on a year-on-year basis. The global pharmaceutical company has a significant market share in India, South Africa and North America. It makes medicines for respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments.
Also Read: India's Mega Projects: World's Largest Solar Park In India Is Spread Over 14,000 Acres
Must Reads
We are an independent and public-spirited digital media platform for Indian millennials. We report news and issues that matter as well as give you the opportunity to take action.
